Brief: Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement
27/10/2023 14:32
Oct 27 (Reuters) - Acumen Pharmaceuticals Inc ABOS.O :
* ACUMEN PHARMACEUTICALS PRESENTS LATE-BREAKER PHASE 1
UPDATES
EXPLORING NOVEL TARGET ENGAGEMENT, DOSING REGIMEN AND SAFETY
FINDINGS FOR ACU193 IN EARLY ALZHEIMER’S DISEASE AT THE 16TH
ANNUAL CLINICAL TRIALS ON ALZHEIMER’S DISEASE
* ACUMEN PHARMACEUTICALS INC - ACUMEN PLANS TO PROGRESS TO A
PHASE
2/3 CLINICAL STUDY, WITH PHASE 2 PORTION PLANNED TO BEGIN IN
FIRST HALF OF 2024
Source text for Eikon: ID:nGNX2DmqzB
Further company coverage: ABOS.O
((Reuters.Briefs@thomsonreuters.com;))